Our Mission

Psilonautica was born out of frustration.Frustration with inefficiency in innovation and application of these revolutionary tools, despite clear promise and need.We’re willing for this technology to be applied with wisdom, and the industry to be one of thriving.To do so, it must be built in a legal, ethical and safe way, and employ skilful communication. With industry regulations and practices being written alongside its growth, the experience of our advisors can help foresee and navigate the challenges and opportunities of this powerful work.

Our Partners

Psilonautica is uniquely positioned to facilitate connections, foster development, and offer unparalleled support to a range of enterprises championing the psychedelic renaissance.

The Canadian 'Special Access Program':
Tip sheet for providers, suppliers and patients

Welcome to the first edition of the MAPS Canada SAP Tip Sheet. This is a helpful and timely resource for patients, healthcare providers and suppliers (SAP stakeholders) looking to access Psychedelic-Assisted-Therapy (PAT) through Health Canada's Special Access Program.Included is a detailed overview of the application process, common responses from Health Canada, relevant questions and answers, in addition to SAP templates and other helpful resources. At present, the focus is centered around Psilocybin and MDMA, as these are the two psychedelic compounds Health Canada has approved applications for thus far.

From Taboo to Treatment:
The Case for Compassionate Access to Psilocybin in the UK

Psilocybin has shown promise as a treatment for existential distress, a condition marked by feelings of hopelessness, despair, and a lack of meaning or purpose in life following a terminal diagnosis. Recent studies have found that Psilocybin Assisted Psychotherapy can lead to significant improvements in mood, anxiety, and quality of life.By embracing alternative treatments such as psilocybin-assisted therapy, the UK can offer a compassionate and meaningful end-of-life experience for those facing existential distress.

Know Your Rights:
Medical Cannabis in the UK

Cannabis-Based Prescribed Medicines have been available in the UK since 2019. These medicines are permitted for the treatment of various medical conditions, provided an individual demonstrates exceptional clinical necessity and has exhausted at least two alternative treatment options without success.The rollout of Cannabis-Based Prescribed Medicines has been tumultuous and has left patients, employers, and UK police forces confused regarding their rights and the law. This document aims to alleviate some of that confusion.

Public Attitudes to Psilocybin-Assisted Therapy in the UK

Public perceptions of psilocybin-assisted therapy have been revealed in this YouGov poll, commissioned by Drug Science. This is the first nationally representative poll of UK attitudes towards the medicalisation of psilocybin and support for policy changes (such as rescheduling psilocybin) to make this happen.The YouGov poll asked 1,763 adults, representing all demographics, political leanings, and regions of the UK, questions about psilocybin-assisted therapy and found rather surprising results. The questions were drafted by PsiloNautica and approved by both Drug Science and YouGov.